BioTuesdays

Category - Markets

ADMA Biologics Logo
Markets

Dawson James starts ADMA Biologics at buy; PT $7

Dawson James initiated coverage of ADMA Biologics (NASDAQ:ADMA) with a “buy” rating and $7 price target. The stock closed at $2.34 on Dec. 27. ADMA is focused on bringing a high-value, potent intravenous immunoglobulin...

December 28, 2018
Corbus Pharmaceuticals
Markets

HCW starts Corbus Pharma at buy; PT $24

H.C. Wainwright initiated coverage of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) with a “buy” rating and $24 price target. The stock closed at $5.26 on Dec. 24. The company’s lead compound, lenabasum, is a...

December 26, 2018
NeuroMetrix
Markets

HCW starts NeuroMetrix at buy; PT $5

H.C. Wainwright launched coverage of NeuroMatrix (NASDAQ:NURO) with a “buy” rating and price target of $5. The stock closed at 68 cents on Dec. 24. NeuroMetrix is a healthcare technology company that has two products on...

December 26, 2018
Translate Bio Logo
Markets

HCW starts Translate Bio at buy; PT $21

H.C. Wainwright initiated coverage of Translate Bio (NASDAQ:TBIO) with a “buy” rating and $21 price target. The stock closed at $8.05 on Dec. 24. Translate Bio is developing treatments for diseases caused by an absence...

December 24, 2018
AnaptysBio
Markets

HCW starts AnaptysBio at buy; PT $126

H.C. Wainwright initiated coverage of AnaptysBio (NASDAQ:ANAB) with a “buy” rating and price target of $126. The stock closed at $60.54 on Dec. 19. While AnaptysBio has emerged as a newcomer in the competitive field of...

December 21, 2018
Dova Pharmaceuticals
Markets

HCW starts Dova Pharma at buy; PT $18

H.C. Wainwright initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “buy” rating and price target of $18. The stock closed at $5.73 on Dec.19. Dova is developing a new thrombopoietin receptor alpha agonist...

December 21, 2018